rs104894005 — GCK Glu279Ter (MODY2)

GCK Glu279Ter — The Mutation That Founded MODY2

In 1992, a French research team identified the first nonsense mutation in the glucokinase gene and, in doing so, answered a decades-old question: why do some families pass down mild diabetes through every generation as if it were hair colour? The answer was an amber stop codon — a single nucleotide change (c.835G>T) that turns codon 279 from GAG (glutamic acid) to TAG (stop), truncating the glucokinase protein at position 279 and abolishing its function in the affected allele. Vionnet et al. 1992¹¹ Vionnet et al. 1992
Vionnet N et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature, 1992 — published in Nature — was the first direct proof that a mutation in a glucose-metabolism enzyme causes human diabetes. This variant is OMIM 138079.0001: allelic variant number one in the glucokinase gene.

The Mechanism

Glucokinase²² Glucokinase
Glucokinase (hexokinase-4) phosphorylates glucose to glucose-6-phosphate in pancreatic beta cells and hepatocytes. Its sigmoidal kinetics and low glucose affinity make it uniquely suited as a "glucose sensor" — activity rises steeply above approximately 5 mmol/L, triggering insulin release proportionally to glucose concentration is the molecular switch that decides when the beta cell releases insulin. The switch only flips when glucose is high enough — specifically above the enzyme's half-saturation concentration of roughly 7–8 mmol/L under physiological conditions. Glu279 is located in a structurally important region of the glucokinase catalytic domain; the p.Glu279Ter nonsense variant introduces a premature stop codon³³ premature stop codon
A stop codon terminates protein synthesis, producing a truncated, non-functional protein. The resulting mRNA is often degraded by nonsense-mediated mRNA decay, so no truncated protein accumulates — the allele is functionally null that truncates the protein by 186 amino acids, rendering it completely non-functional.

In a heterozygous carrier, one fully functional GCK copy remains. Half-normal glucokinase activity shifts the glucose set-point for insulin secretion upward by approximately 1.4–2.0 mmol/L. The pancreas defends a higher fasting glucose — roughly 5.5–8.0 mmol/L (99–144 mg/dL) — throughout life. This is not beta-cell failure; it is a fixed recalibration of the glucose thermostat, present from conception, stable over decades, and not progressive.

The Evidence

Vionnet et al. 1992⁴⁴ Vionnet et al. 1992
Vionnet N et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature, 1992 identified the Glu279Ter variant in a French family through single-strand conformation polymorphism analysis of GCK exon 7. All affected family members with this stop codon had the characteristic MODY phenotype — early-onset mild hyperglycemia with autosomal dominant transmission. This was published simultaneously with Froguel et al.⁵⁵ Froguel et al.
Froguel P et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature, 1992, which established glucokinase linkage in 16 French MODY families, and Hattersley et al.⁶⁶ Hattersley et al.
Hattersley AT et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet, 1992 confirming the same in a British five-generation pedigree.

The definitive natural history comes from Velho et al. 1997⁷⁷ Velho et al. 1997
Velho G et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia, 1997: 260 subjects across 42 families showed mild fasting hyperglycemia, fewer than 50% with overt diabetes by WHO criteria, and a strikingly low prevalence of microvascular complications despite lifelong glucose elevation. Chakera et al. 2015⁸⁸ Chakera et al. 2015
Chakera AJ et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care, 2015 synthesized this evidence into the current management consensus: fasting glucose 5.4–8.3 mmol/L and HbA1c 5.8–7.6% are expected and stable; even after 50 years of this elevation, patients do not develop significant diabetic retinopathy or nephropathy; glucose-lowering treatment is ineffective and not recommended outside pregnancy.

Practical Actions

The most important clinical consequence of identifying this variant is preventing misdiagnosis and unnecessary treatment. An estimated 80% of GCK-MODY individuals in the general population carry a diagnosis of type 1 or type 2 diabetes and are on medications that provide no benefit. Metformin, sulfonylureas, and insulin cannot override the glucokinase set-point mechanism and do not normalise glucose in confirmed GCK-MODY heterozygotes. Stopping unnecessary medication removes side-effect risk, hypoglycaemia exposure, and medication burden without any glycaemic cost.

Pregnancy is the exception. When a GCK-MODY carrier is pregnant, the key variable is the fetal genotype. An unaffected fetus responds to maternal hyperglycaemia with excess insulin, causing macrosomia. An affected fetus has its own elevated set-point and grows normally. Fetal abdominal circumference on ultrasound every two weeks from 26 weeks⁹⁹ Fetal abdominal circumference on ultrasound every two weeks from 26 weeks
Rudland VL. Diagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectives. Diabetes Metab Syndr Obes, 2019 is the standard surrogate for fetal genotype: AC exceeding the 75th centile indicates an unaffected fetus and warrants insulin therapy; AC at or below the 50th centile suggests the fetus has inherited the variant and no treatment is needed. Non-invasive fetal genotyping via cell-free fetal DNA is now available in specialist centres and removes this ambiguity.

Interactions

Carriers of additional common type 2 diabetes risk alleles (such as rs5219 in KCNJ11 or rs7903146 in TCF7L2) may have a modestly worse glycaemic trajectory as these variants independently impair beta-cell function downstream of glucokinase. Clinically, the GCK-MODY phenotype typically dominates, but midlife weight gain or insulin resistance may compound the glucose elevation beyond the expected stable range — patients with GCK-MODY whose glycaemia worsens meaningfully after age 40 warrant reassessment.

Homozygous or compound heterozygous GCK mutations (two pathogenic alleles) abolish glucokinase activity entirely, causing permanent neonatal diabetes requiring insulin from birth — a qualitatively different, far more serious condition than heterozygous MODY2. Parents who are both heterozygous GCK-MODY carriers face a 25% probability per pregnancy of an affected homozygous infant, and should discuss preconception genetic counselling.